InflaRx Announces Participation in January Events in San Francisco
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has announced its participation in multiple events during the week of January 13, 2025, in San Francisco. The company will attend the LifeSci Partners Corporate Access Event for one-on-one meetings on January 14-15, and participate in a workshop at Biotech Showcase 2025 on January 15 titled 'The Need for Novel Responses to Disease Threat(s) in a Fast-Changing World.'
InflaRx specializes in developing inhibitors of the complement activation factor C5a and its receptor C5aR. Their lead product candidate, vilobelimab, is an intravenous anti-C5a monoclonal antibody. The company is also developing INF904, an oral C5a receptor inhibitor. Founded in 2007, InflaRx maintains offices in Jena and Munich, Germany, and Ann Arbor, MI, USA.
InflaRx N.V. (Nasdaq: IFRX), una compagnia biofarmaceutica focalizzata sui farmaci anti-infiammatori, ha annunciato la sua partecipazione a più eventi durante la settimana del 13 gennaio 2025 a San Francisco. L'azienda parteciperà all'LifeSci Partners Corporate Access Event per incontri individuali il 14 e 15 gennaio e parteciperà a un workshop al Biotech Showcase 2025 il 15 gennaio intitolato 'La necessità di risposte innovative alle minacce per la salute in un mondo in rapido cambiamento.'
InflaRx è specializzata nello sviluppo di inibitori del fattore di attivazione del complemento C5a e del suo recettore C5aR. Il loro principale candidato al prodotto, vilobelimab, è un anticorpo monoclonale anti-C5a somministrato per via endovenosa. L'azienda sta anche sviluppando INF904, un inibitore del recettore C5a per uso orale. Fondata nel 2007, InflaRx ha uffici a Jena e Monaco, in Germania, e ad Ann Arbor, MI, USA.
InflaRx N.V. (Nasdaq: IFRX), una compañía biofarmacéutica centrada en terapias antiinflamatorias, ha anunciado su participación en múltiples eventos durante la semana del 13 de enero de 2025 en San Francisco. La empresa asistirá al LifeSci Partners Corporate Access Event para reuniones uno a uno los días 14 y 15 de enero, y participará en un taller en el Biotech Showcase 2025 el 15 de enero titulado 'La necesidad de nuevas respuestas a las amenazas de enfermedades en un mundo en constante cambio.'
InflaRx se especializa en el desarrollo de inhibidores del factor de activación del complemento C5a y su receptor C5aR. Su principal candidato a producto, vilobelimab, es un anticuerpo monoclonal anti-C5a administrado por vía intravenosa. La empresa también está desarrollando INF904, un inhibidor del receptor C5a por vía oral. Fundada en 2007, InflaRx tiene oficinas en Jena y Múnich, Alemania, y Ann Arbor, MI, EE. UU.
InflaRx N.V. (Nasdaq: IFRX), 항염 치료제에 중점을 둔 생명공학 회사는 2025년 1월 13일 주에 샌프란시스코에서 여러 행사에 참여한다고 발표했습니다. 이 회사는 1월 14일과 15일에 일대일 회의가 열리는 LifeSci Partners Corporate Access Event에 참석하고, 1월 15일에 Biotech Showcase 2025에서 '빠르게 변화하는 세상에서 질병 위협에 대한 새로운 반응의 필요성'이라는 제목의 워크숍에 참가할 예정입니다.
InflaRx는 C5a 및 그 수용체 C5aR의 보완 활성화 인자 억제제 개발을 전문으로 합니다. 그들의 주요 제품 후보인 vilobelimab는 정맥 주사용 항-C5a 단일클론 항체입니다. 이 회사는 또한 복용 가능한 C5a 수용체 억제제인 INF904를 개발하고 있습니다. 2007년에 설립된 InflaRx는 독일 예나 및 뮌헨, 미국 미시간주 앤아버에 사무소를 두고 있습니다.
InflaRx N.V. (Nasdaq: IFRX), une entreprise biopharmaceutique axée sur les thérapies anti-inflammatoires, a annoncé sa participation à plusieurs événements durant la semaine du 13 janvier 2025 à San Francisco. L'entreprise assistera à l'LifeSci Partners Corporate Access Event pour des réunions individuelles les 14 et 15 janvier et participera à un atelier au Biotech Showcase 2025 le 15 janvier intitulé 'Le besoin de nouvelles réponses face aux menaces de maladies dans un monde en rapide mutation.'
InflaRx se spécialise dans le développement d'inhibiteurs du facteur d'activation du complément C5a et de son récepteur C5aR. Leur principal candidat produit, vilobelimab, est un anticorps monoclonal anti-C5a administré par voie intraveineuse. L'entreprise développe également INF904, un inhibiteur du récepteur C5a à usage oral. Fondée en 2007, InflaRx a des bureaux à Jena et Munich, en Allemagne, et à Ann Arbor, MI, USA.
InflaRx N.V. (Nasdaq: IFRX), ein biopharmazeutisches Unternehmen, das sich auf entzündungshemmende Therapeutika spezialisiert hat, hat seine Teilnahme an mehreren Veranstaltungen in der Woche vom 13. Januar 2025 in San Francisco bekannt gegeben. Das Unternehmen wird am LifeSci Partners Corporate Access Event am 14. und 15. Januar an Einzelgesprächen teilnehmen und an einem Workshop beim Biotech Showcase 2025 am 15. Januar mit dem Titel 'Die Notwendigkeit neuer Antworten auf Krankheitsbedrohungen in einer sich schnell verändernden Welt' teilnehmen.
InflaRx hat sich auf die Entwicklung von Inhibitoren des Komplementaktivierungsfaktors C5a und seines Rezeptors C5aR spezialisiert. Ihr Spitzenkandidat, vilobelimab, ist ein intravenös verabreichter anti-C5a monoklonaler Antikörper. Das Unternehmen entwickelt auch INF904, einen oralen C5a-Rezeptor-Inhibitor. Gegründet im Jahr 2007, hat InflaRx Büros in Jena und München, Deutschland, sowie in Ann Arbor, MI, USA.
- None.
- None.
JENA, Germany, Jan. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple events the week of January 13, 2025, in San Francisco, CA. This activity will take place during the week of the 43rd Annual J.P. Morgan Healthcare Conference.
LifeSci Partners Corporate Access Event
1-on-1 meetings on January 14 and 15, 2025
Biotech Showcase 2025
Workshop on January 15, 2025, 8:00 – 9:00 AM PT
The Need for Novel Responses to Disease Threat(s) in a Fast-Changing World: A Q&A with Government, NGO and Industry Participants
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications. InflaRx is also developing INF904, an orally administered, small molecule inhibitor of the C5a receptor. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de | Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the headings, “Risk factors” and “Cautionary statement regarding forward looking statements”, in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
What events will InflaRx (IFRX) attend in San Francisco in January 2025?
What is InflaRx's (IFRX) lead product candidate?
What therapeutic areas does InflaRx (IFRX) focus on?
What products are currently in InflaRx's (IFRX) development pipeline?
